Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)
Historic Accumulated Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $27.0 million.
- Inhibrx Biosciences' Accumulated Expenses fell 979.26% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 979.26%. This contributed to the annual value of $29.9 million for FY2024, which is 3096.2% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Accumulated Expenses is $27.0 million, which was down 979.26% from $28.5 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Accumulated Expenses ranged from a high of $43.3 million in Q4 2023 and a low of $23.9 million during Q2 2024
- Over the past 3 years, Inhibrx Biosciences' median Accumulated Expenses value was $29.9 million (recorded in 2024), while the average stood at $30.7 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 3096.2% in 2024, then soared by 1935.46% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Accumulated Expenses stood at $43.3 million in 2023, then crashed by 30.96% to $29.9 million in 2024, then fell by 9.79% to $27.0 million in 2025.
- Its last three reported values are $27.0 million in Q3 2025, $28.5 million for Q2 2025, and $32.8 million during Q1 2025.